Multiplex Assay Kit for Terminal Complement Complex C5b-9 (C5b-9) ,etc. by FLIA (Flow Luminescence Immunoassay) 
MAC; Membrane Attack Complex
(Note: Up to 8-plex in one testing reaction)
- UOM
- FOB US$ 449.00 US$ 467.00 US$ 492.00 US$ 527.00 US$ 562.00 US$ 613.00 US$ 691.00 US$ 864.00
- Quantity
Overview
Properties
- Product No.LMC350Mu
- Organism SpeciesMus musculus (Mouse) Same name, Different species.
- ApplicationsFLIA Kit for Antigen Detection.
Research use only - DownloadInstruction Manual
- CategorySignal transductionMetabolic pathwayApoptosisInfection immunity
Sign into your account
Share a new citation as an author
Upload your experimental result
Review
Contact us
Please fill in the blank.
-
Packages (Simulation)
-
Packages (Simulation)
-
Results demonstration
-
Typical Standard Curve
-
ISO9001: 2008, ISO13485: 2003 Registered
Recovery
Matrices listed below were spiked with certain level of recombinant Terminal Complement Complex C5b-9 (C5b-9) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Terminal Complement Complex C5b-9 (C5b-9) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.
| Matrix | Recovery range (%) | Average(%) |
| serum(n=5) | 81-91 | 87 |
| EDTA plasma(n=5) | 84-101 | 95 |
| heparin plasma(n=5) | 84-98 | 88 |
| sodium citrate plasma(n=5) | 84-99 | 92 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Terminal Complement Complex C5b-9 (C5b-9) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Terminal Complement Complex C5b-9 (C5b-9) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Terminal Complement Complex C5b-9 (C5b-9) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 83-97% | 93-101% | 92-105% | 91-99% |
| EDTA plasma(n=5) | 78-95% | 93-101% | 78-88% | 99-105% |
| heparin plasma(n=5) | 98-105% | 83-93% | 82-101% | 97-104% |
| sodium citrate plasma(n=5) | 93-101% | 93-101% | 79-98% | 88-98% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
| Reagents | Quantity | Reagents | Quantity |
| 96-well plate | 1 | Plate sealer for 96 wells | 4 |
| Pre-Mixed Standard | 2 | Standard Diluent | 1×20mL |
| Pre-Mixed Magnetic beads (22#:C5b-9) | 1 | Analysis buffer | 1×20mL |
| Pre-Mixed Detection Reagent A | 1×120μL | Assay Diluent A | 1×12mL |
| Detection Reagent B (PE-SA) | 1×120μL | Assay Diluent B | 1×12mL |
| Sheath Fluid | 1×10mL | Wash Buffer (30 × concentrate) | 1×20mL |
| Instruction manual | 1 |
Assay procedure summary
1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.
Test principle
Analyte-specific antibodies are pre-coated onto color-coded microparticles. Microparticles, standards, and samples are pipetted into wells and the immobilized antibodies bind the analytes of interest. After washing away any unbound substances, a biotinylated antibody cocktail specific to the analytes of interest is added to each well. Following a wash to remove any unbound biotinylated antibody, Streptavidin-Phycoerythrin conjugate (Streptavidin-PE), which binds to the biotinylated detection antibodies, is added to each well. A final wash removes unbound Streptavidin-PE and the microparticles are resuspended in buffer and read using the Luminex or Bio-Plex analyzer.The MFI developed is proportional to the concentration of analytes of interest in the sample.
Giveaways
Increment services
Citations
- Effect of thiol functionalization on the hemo-compatibility of PLGA nanoparticlesWiley: source
- Complement component 5 contributes to poor disease outcome in humans and mice with pneumococcal meningitisPubMed: PMC3195471
- Glucosylated polymeric nanoparticles: A sweetened approach against blood compatibility paradoxScienceDirect: S0927776513001720
- The effect of normovolemic modified ultrafiltration on inflammatory mediators, endotoxins, terminal complement complexes and clinical outcome in high-risk cardiac surgery patientsPubmed: 23429100
- The efficacy of recombinant human soluble thrombomodulin for the treatment of shiga toxin associated hemolytic uremic syndrome model micePubmed:25694534
- Adjuvant treatment with dexamethasone plus anti-C5 antibodies improves outcome of experimental pneumococcal meningitis: a randomized controlled trialPubMed: 26272468
- Thrombin‐activatable fibrinolysis inhibitor influences disease severity in humans and mice with pneumococcal meningitisPubMed: 26340319
- Dosagem de frações ativadas do sistema complemento em empiema induzido em ratos10183
- Mannose-binding lectin-associated serine protease 2 (MASP-2) contributes to poor disease outcome in humans and mice with pneumococcal meningitisPMC5234106
- Complement C5a/C5aR pathway potentiates the pathogenesis Q5 of gastric cancer by down-regulating p21 expressionpubmed:29031586
- Effects of immunoadsorption combined with membrane filtration on complement markers–Results of a randomized, controlled, crossover study
- Complement factor H contributes to mortality in humans and mice with bacterial meningitisPubmed: 31883521
- C‐reactive protein inhibits C3a/C3aR‐dependent podocyte autophagy in favor of diabetic kidney diseasePubmed:35503088